Roche and Boehringer Ingelheim this week partnered with technology companies to develop and deploy wearable biosensor technology for use in clinical trials and patient monitoring.
Alliance between Roche and France Sysnavi Healthcare Built on the technology company’s wearable magnetic-inertial sensor device for 3D movement tracking in the field of movement disorders and already accepted as a digital endpoint for use in the European Medicines Agency’s Duchenne Muscular Dystrophy (DMD) clinical trial agency (EMA).
Partners will work together to create industry-standard digital endpoints suitable to monitor disease progression, support clinical trials, and serve as regulatory-approved standards for outcome measurement, and design next-generation technologies. .
SysNav has already developed two wearables based on this technology. namely, her ActiMyo device for clinical trials and Syde for recording real-world data. It can track movement but does not rely on GPS positioning and protects patient privacy.
“Sysnav’s technology provides an opportunity to measure functional disease progression to regulatory standards for a variety of diseases,” said James Sabry, Head of Pharmaceutical Partners at Roche.
“This could improve how patients participate in clinical research, their ability to determine potential therapeutic effects, and their ability to gain a better understanding of disease pathophysiology,” he added.
Roche has marketed medicines for multiple sclerosis (Ocrevus) and spinal muscular atrophy (Evrysdi) and has a pipeline of new treatments for multiple sclerosis, DMD, Parkinson’s disease and neuromuscular diseases, including exercise Already an established player in the field of diseases that affect
Damien Eggenspieler, Head of Healthcare Programs at Sysnav, said:
Meanwhile, Boehringer is partnering with a US company Strados Lab A future idiopathic pulmonary fibrosis (IPF) pilot study will use an FDA-approved lung wearable RESP biosensor.
In the coming weeks, Boehringer will use the device to remotely monitor patients’ coughs and crackles at home. These symptoms may worsen the outcome of IPF. The pilot will investigate how the device can be used to monitor a patient’s condition in hopes of using it in the development of a new her IPF therapy.
The German pharmaceutical group has already marketed a widely used tyrosine kinase inhibitor for IPF called Ofev (nintedanib) and is developing a PDE 4B inhibitor called BI 101550 in phase 2 trials.
According to Nick Delmonico, CEO and co-founder of Strados Labs, “Currently, disease progression in IPF is measured by a decline in forced vital capacity (FVC).
“We are pleased that Boehringer Ingelheim is investigating coughing and crackling as an additional way to monitor disease and help patients stay in the comfort of their own home.”
